Literature DB >> 3740986

Cyclosporin for polymyositis.

S van der Meer, J W Imhof, J C Borleffs.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3740986      PMCID: PMC1001947          DOI: 10.1136/ard.45.7.612-a

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  2 in total

1.  Cyclosporin for acute dermatomyositis.

Authors:  P Zabel; G Leimenstoll; W L Gross
Journal:  Lancet       Date:  1984-02-11       Impact factor: 79.321

2.  Cyclosporin for polymyositis.

Authors:  K Bendtzen; N Tvede; V Andersen; G Bendixen
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

  2 in total
  6 in total

1.  Polymyositis and cyclosporin A.

Authors:  J Alijotas; J Barquinero; J Ordi; M Vilardell
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

2.  Treatment of Wegener's granulomatosis with cyclosporin.

Authors:  J C Borleffs; R H Derksen; R J Hené
Journal:  Ann Rheum Dis       Date:  1987-02       Impact factor: 19.103

Review 3.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

4.  Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis.

Authors:  M G Danieli; G Malcangi; C Palmieri; F Logullo; A Salvi; M Piani; G Danieli
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

6.  Dermatomyositis treated with cyclosporin.

Authors:  G M Kavanagh; J S Ross; M M Black
Journal:  J R Soc Med       Date:  1991-05       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.